Navigation Links
ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference
Date:5/4/2010

NEW ORLEANS, May 4 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1).   Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%. The difference in remission rate between the two groups was statistically significant (p=0.01) at week 36. Also, at week 36, a statistically significant percentage of patients receiving Traficet-EN versus placebo were in corticosteroid-free remission and had normalized C-reactive protein (CRP) levels.  Traficet-EN continued to be safe and well-tolerated for the entire course of the PROTECT-1 study (aggregate dosing up to one year). These data were presented today in an oral session at the Digestive Disease Week (DDW) conference in New Orleans by Satish Keshav, M.D., Ph.D., Department of Gastroenterology, John Radcliffe Hospital, Oxford University.

The results from the Maintenance period of PROTECT-1 reported here confirmed and expanded the efficacy of Traficet-EN that was observed in the preceding Induction period of the study, which was reported in 2009.

"Treatment for inflammatory diseases of the bowel including Crohn's has been woefully insufficient for far too long for such a devastating disease," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "We believe Traficet-EN represents a paradigm shift in terms of safety and efficacy for these patients, of
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 25, 2014  Medtronic,s roughly $43 ... been widely discussed in the media for its ... a stronger leading player in one of the ... The healthcare market research firm said  the two ... a diverse set of solutions spanning inpatient to ...
(Date:11/26/2014)... YORK, Pa. , Nov. 25, 2014  Unilife ... supplier of injectable drug delivery systems, today announced that ... scheduled to present at the Piper Jaffray 26th Annual ... 8:30 a.m. EST on Tuesday, December 2, 2014. ... the Internet as a "live" listen only Webcast. To ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 ... (NYSE: AZN ) today announced that AMAGINE-2 TM ... of brodalumab in more than 1,800 patients with moderate-to-severe plaque ... ® (ustekinumab) and placebo at week 12. Brodalumab 210 ... group were each shown to be superior to Stelara on ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... UPI ) announced today that it will release financial ... at the market close on Monday, November 2, 2009. ... results on Monday, November 2, 2009 at 3:30 p.m. Central ... Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will ...
... 21 Shire plc,(LSE: SHP, NASDAQ: SHPGY ), ... Biologics License Application (BLA) with the U.S.,Food and Drug ... for Fabry disease, by the end of the year. ... filed at the,request of FDA, has been approved, and ...
Cached Medicine Technology:Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 3Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 4
(Date:11/26/2014)... NY (PRWEB) November 26, 2014 Call ... research requirements or email the details on sales(at)researchmoz(dot)us ... diabetes and drug discovery market 2014" with deep study ... is the result of high blood sugar. The global ... directly linked to the growing number of diabetics in ...
(Date:11/26/2014)... Aurora, CO (PRWEB) November 26, 2014 For ... fast, the new LES MILLS BODYPUMP™ classes at ... be just the workout they've been looking for. The 45- ... with CU Anschutz Health and Wellness Center fitness club memberships. ... muscles. The workouts are fast-paced and are aimed at fast ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, ... Distinguished Preceptorship Award from The American Association ... the advancement of nurse practitioners. The Distinguished Preceptorship ... had made a significant contribution toward increasing the ... of Nurse Practitioners (AANP) is the largest full-service ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Vultures have developed highly ... ingest when eating dead animals, researchers report. The ... on the faces and in the guts of 50 ... On average, the faces of the vultures had more ... in their guts, the study found. The findings ...
(Date:11/26/2014)... -- Exposure to peanut protein in household dust may ... the skin condition eczema, a new study reveals. ... States are allergic to peanuts. And severe eczema in ... allergy, the researchers noted. The new study included ... researchers examined the amount of peanut protein the children ...
Breaking Medicine News(10 mins):Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2
... opposite trend, latest one reflects entire U.S. population, experts ... some recent research has documented an upswing in mastectomy ... cancer, a new study comes to a different conclusion. ... decrease overall nationwide," said study author Dr. Elizabeth Habermann, ...
... ... Appeal and Wellness Benefits for Gamers , ... Los Angeles, CA (Vocus) June 15, 2010 -- Beamz Interactive , an ... of all ages and skill levels to play music, today announced a strategic partnership with ...
... the June edition of the Journal of Thoracic ... surgical outcomes of patients with non-small cell lung cancer ... cancer continues to rise; therefore, countermeasures to decrease death ... analyzing the time trends, researchers postulated that the increase ...
... This ... style and function are now standard accessories for most dog owners. The Rubit! provides a quick ... or the danger of a broken fingernail.The clip functions between the collar and an ID tags ... (PRWEB) June 15, 2010 ...
... new cancer medication sorafenib looks promising. Sorafenib is used ... to be effective against cancer stem cells in pancreatic ... Head of the Department of Molecular Oncosurgery, a group ... (Managing Director: Professor Dr. Markus W. Bchler) in cooperation ...
... reason why depression and other stress-related psychiatric disorders are ... signaling systems in animal brains, neuroscience researchers found that ... important stress hormone and less able to adapt to ... evidence for sex differences in how neurotransmitter receptors traffic ...
Cached Medicine News:Health News:Mastectomy Rates Down Overall, New Study Finds 2Health News:Mastectomy Rates Down Overall, New Study Finds 3Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 2Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 3Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 4Health News:Lung cancer research concludes that early diagnosis as key for improving survival 2Health News:The Rubit Dog Tag Clips Making Big Pet Store Sales, Everyday Dog Ownership Easier, Preventing Broken Fingernails. 2Health News:New combination effective against pancreatic cancer 2Health News:Higher anxiety, depression among women may have basis in cell signals 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: